Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Возможности коррекции высокой остаточной реактивности тромбоцитов на терапии дезагрегантами1
Возможности коррекции высокой остаточной реактивности тромбоцитов на терапии дезагрегантами1
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Полный текст
Список литературы
1. Brar SS, Ten Berg J, Marcucci R et al. Impact of platelet reactivity on clinical outcomes after pecutaneous coronary intervention a collaborative meta-analysis of individual participant data.
J Am Coll Cardiol 2011; 58 (19): 1945–4.
2. Bonello L, Tantry US, Marcucci R. et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 2010; 56: 919–3.
3. Sibbing D, Morath T, Braun S et al. Clopidogrel response status assessed with Multiplate point-of-care analysis and the incidence and timing of stent thrombosis over six months following coronary stenting. Thromb Haemost 2010; 103: 151–9.
4. Geisler T, Zurn Ch, Simonenko R et al. Early but not late stent thrombosis is influensed by residual platelet aggregation in patients undergoing coronary interventions. Eur Heart J 2010; 31: 59–6.
5. Breet NJ, van Werkum JW, Bouman IIJ et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. J Am Med Assoc 2010; 303: 754–2.
6. Bliden KP, Di Chiara J, Looxman L et al. The association of cigarette smoking with enhanced plateled inhibition by clopidogrel. J Am Coll Cardiol 2008, 52: 531–3.
7. Desai NR, Mega JL, Jiang S et al. Interaction between cigarette smoking and clinical benefit of clopidogrel. J Am Col. Cardiol 2009; 53: 1273–8.
8. Beitleshees AL. March 29, 2012, www.thelancet.com.
9. Von Beckerath N, Rastrati A, Wiekzorek A et al. A double-blind, randomised study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days. Eur Heart J 2007; 28: 1814–9.
10. Mehta SR, Bassand JP, Chrolavicians S et al. CURREN-OASIS 7 investigators. Dose comparisons of clopidogrel and aspirin in acute coronary syndrome. N Engl J Med 2010; 363: 930–2.
11. TRITON-TIMI 38 Investigators. Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial. Eur Heart J 2009; 30: 1753–3.
12. Hochholzer W, Trenk D, Bestehorn HP et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol 2006; 48: 1742–50.
13. Geisler T, Zurn Ch, Simonenko R et al. Early but not late stent thrombosis is influensed by residual platelet aggregation in patients undergoing coronary interventions. Eur Heart J 2010; 31: 59–6.
14. Price MJ, Berger PB, Teirstein PS et al. GRAVITAS investigators. Standard – vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomised trial. J Am Med Assoc 2011; 305: 1097–05.
15. Lomonosova AA, Mazur NA, Zolozova EA et al. Residual platelet reactivity during therapy with inhibitors of cyclooxigenase or adenosine diphosphate receptors. Rational Pharmacother Card 2012; 8 (2): 168–2. Russian (Ломоносова А.А., Мазур Н.А., Золозова Е.А. и др. Остаточная реактивность тромбоцитов на терапии ингибиторами циклооксигеназы или рецепторов аденозиндифосфата. Рациональная фармакотерапия в кардиологии. 2012; 8 (2): 168–2).
16. Serebruany VL. Viewpoint: Paradoxial excess mortality in the PLATO trial should be independently verified. Thrombosis and Haemostasis 2011, 105: 752–9.
J Am Coll Cardiol 2011; 58 (19): 1945–4.
2. Bonello L, Tantry US, Marcucci R. et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 2010; 56: 919–3.
3. Sibbing D, Morath T, Braun S et al. Clopidogrel response status assessed with Multiplate point-of-care analysis and the incidence and timing of stent thrombosis over six months following coronary stenting. Thromb Haemost 2010; 103: 151–9.
4. Geisler T, Zurn Ch, Simonenko R et al. Early but not late stent thrombosis is influensed by residual platelet aggregation in patients undergoing coronary interventions. Eur Heart J 2010; 31: 59–6.
5. Breet NJ, van Werkum JW, Bouman IIJ et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. J Am Med Assoc 2010; 303: 754–2.
6. Bliden KP, Di Chiara J, Looxman L et al. The association of cigarette smoking with enhanced plateled inhibition by clopidogrel. J Am Coll Cardiol 2008, 52: 531–3.
7. Desai NR, Mega JL, Jiang S et al. Interaction between cigarette smoking and clinical benefit of clopidogrel. J Am Col. Cardiol 2009; 53: 1273–8.
8. Beitleshees AL. March 29, 2012, www.thelancet.com.
9. Von Beckerath N, Rastrati A, Wiekzorek A et al. A double-blind, randomised study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days. Eur Heart J 2007; 28: 1814–9.
10. Mehta SR, Bassand JP, Chrolavicians S et al. CURREN-OASIS 7 investigators. Dose comparisons of clopidogrel and aspirin in acute coronary syndrome. N Engl J Med 2010; 363: 930–2.
11. TRITON-TIMI 38 Investigators. Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial. Eur Heart J 2009; 30: 1753–3.
12. Hochholzer W, Trenk D, Bestehorn HP et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol 2006; 48: 1742–50.
13. Geisler T, Zurn Ch, Simonenko R et al. Early but not late stent thrombosis is influensed by residual platelet aggregation in patients undergoing coronary interventions. Eur Heart J 2010; 31: 59–6.
14. Price MJ, Berger PB, Teirstein PS et al. GRAVITAS investigators. Standard – vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomised trial. J Am Med Assoc 2011; 305: 1097–05.
15. Lomonosova AA, Mazur NA, Zolozova EA et al. Residual platelet reactivity during therapy with inhibitors of cyclooxigenase or adenosine diphosphate receptors. Rational Pharmacother Card 2012; 8 (2): 168–2. Russian (Ломоносова А.А., Мазур Н.А., Золозова Е.А. и др. Остаточная реактивность тромбоцитов на терапии ингибиторами циклооксигеназы или рецепторов аденозиндифосфата. Рациональная фармакотерапия в кардиологии. 2012; 8 (2): 168–2).
16. Serebruany VL. Viewpoint: Paradoxial excess mortality in the PLATO trial should be independently verified. Thrombosis and Haemostasis 2011, 105: 752–9.
Авторы
Н.А.Мазур, А.А.Ломоносова, Е.А.Золозова, Е.В.Саютина, В.В.Чигинева
ГБОУ ДПО РМАПО, Москва
ГБОУ ДПО РМАПО, Москва
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.